{"entity":{"id":"nct05566795","kind":"trial","name":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","aka":["FIREFLY-2"],"tldr":"A phase 3 trial of Tovorafenib in glioma & glioblastoma, run by Day One Biopharmaceuticals, Inc., active and no longer recruiting.","summary":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) is a phase 3 interventional study registered as NCT05566795 by Day One Biopharmaceuticals, Inc., with 418 participants enrolled, started 2023-02-27 and due to reach its primary completion in 2027-06. Interventions recorded: Tovorafenib and Chemotherapeutic Agent.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05566795","url":"https://clinicaltrials.gov/study/NCT05566795"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma","paediatric-low-grade-glioma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["tovorafenib"],"companies":["day-one-biopharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05566795","phase":"3","setting":"LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy","sponsor":"Day One Biopharmaceuticals, Inc.","participation":[{"nct":"NCT05566795","source":"https://clinicaltrials.gov/study/NCT05566795","fetchedAt":"2026-10-07T16:53:46.156Z","studySha256":"2004782bec9f7547dfe924d5246e9677d71d723824e399de51444fae13089eae","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-05-14","leadSponsor":"Day One Biopharmaceuticals, Inc.","collaboratorCount":1,"maximumAge":"25 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":418,"enrolmentType":"ACTUAL","siteCount":138,"recruitingSiteCount":0,"countries":["Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Egypt","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Jordan","Netherlands","New Zealand","Norway","Qatar","Singapore","Slovenia","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom","United States"]}],"started":"2023-02-27","startedType":"actual","enrolled":418,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05566795/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"paediatric-low-grade-glioma","kind":"cancer","name":"Paediatric low-grade glioma","route":"/cancers/paediatric-low-grade-glioma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"tovorafenib","kind":"drug","name":"Tovorafenib","route":"/drugs/tovorafenib/"}],"company":[{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","route":"/companies/day-one-biopharmaceuticals/"}]}}